DocWire News Editors

DocwireNews

Real-world patients with chronic myeloid leukemia (CML) are often different from the ones selected for clinical trial inclusion, according to Giorgina Specchia, MD, of the University of Bari, Italy. At the 60th ASH Annual Meeting and Exposition, Specchia presented results on clinical, hematologic characteristics and treatment response all newly diagnosed patients with CML referred to Italian Hematology Centers of the GIMEMA Study Group between January 2012 and November 2018.For the analysis, the only exclusion criterion was refusal by the patient to participate. All data was recorded in a web-based database and included clinical, hematological, cytogenetic, and biological information. As of November 26, 2018, there were 2,025 patients enrolled.&ldquo;We evaluated 1,200 patients with at least 24 months of follow-up,&rdquo; Specchia said. Recruitment into the study was initially slow, he said, but grew exponentially from 2015 onwards. At this time, 61.5% of patients were male; the median age was 58.5. Of the total 1,096 patients, at diagnosis 1085 (99%) patients were in chronic phase, 8 (0.7%) patients were in accelerated phase and 3 (0.3%) in blastic crisis.When evaluating patients by risk scores, the majority of patients were found to have intermediate risk when the Sokal Index or EURO was used, but EUTOS found no intermediate risk patients (and an overwhelming majority were low risk). The EUTOS Long-Term Survival (ELTS) score also found most patients were low risk (only 40% were considered intermediate or high risk). Comparatively, 60% of patients were considered intermediate or high risk by Sokal.&ldquo;ELTS is more adherent to the biology of the disease,&rdquo; Specchia said.At cytogenetic analysis, there were on 982 patients: 889 (90.6%) had no additional cytogenetic aberrations (ACA), 60 (6.1%) had major route ACA, and 33 (3.3%) had minor route ACA.According to comorbidity and excluding CML diagnosis as a parameter, among 1,158 cases the Charlson comorbidity index was 0, 1, 2 or &ge;3 in 910 (78.6%), 127 (11%), 75 (6.4%) and 52 (4.4%) patients, respectively.When analyzed by type of comorbidity (n=1,200), cardiovascular disease was the most prevalent (26.2%), followed by lung disease (9.7%), and metabolic disease (7%).&ldquo;More than 25% had at least one chronic comorbidity, but 8.1% had other cancers already known at diagnosis,&rdquo; Specchia said. &ldquo;And note, we were excluding CML as a diagnosis.&rdquo;Overall survival (OS) was high, at 95.7% with a median follow-up of 37 months. There were 49 deaths, 12 of which were considered to be related to CML disease progression.When using the Sokal risk scoring (n=1,010), there was no difference in OS at 4 years among patients with low, intermediate, or high risk (P=0.1193). However, there was a statistically significant difference when using the ELTS risk score (n=1,028) between low (98%), intermediate (94.3%) and high-risk (86.8%;P&lt;0.0001).Of the tyrosine kinase inhibitors (TKIs) used as first-line therapy, about one-half of the patients (n=593) were on imatinib while the others were treated with a second-generation TKI. Specchia noted that 356 patients had been pretreated with hydroxyurea.When analyzed by TKI used, OS at 4 years was 93.5% for imatinib and 97.8% for second-generation TKIs. OS at 4 years by ELTS risk found statistically significant differences in patients regardless of which TKI was used.Molecular response was better with second-generation TKIs than imatinib; this difference was highly pronounced early in treatment (with 23.9% vs 5.5% MR3 response at 3 months between second-generation and imatinib, respectively), he said. Similar results were found with MR4 and MR5 responses as well, Specchia said.&ldquo;Our preliminary results of this observational epidemiologic study suggest that collection of clinical data of CML patients treated out of strictly clinical trials represent an essential tool for long-term treatment, [and we are] able to observe setting strategies based on the clinical characteristics, the degree of response obtained, and the toxicity related to the therapy in overall CML population,&rdquo; Specchia said. &ldquo;Molecular responses are faster and deeper with second generation TKIs, and while the OS difference was not statistically significant between TKI treatment groups, it became statistically significant in particular for the ELTS intermediate risk group patients.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Analysis of Real-world Population of Patients with CML Essential

ASH Annual Meeting 2018

Real-world patients with chronic myeloid leukemia (CML) are often different from the ones selected for clinical trial inclusion, according to Giorgina Specchia, MD, of the ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe